PF
PFE
Quarter ended Dec 31, 2025 · FY2025 Q4

Pfizer (PFE) Revenue — Quarter Ended Dec 31, 2025

Revenue rose sequentially but fell compared with the same quarter a year earlier, reflecting mixed trends.

Key takeaway

Quarter ended Dec 31, 2025 · FY2025 Q4

Revenue rose sequentially but fell compared with the same quarter a year earlier, reflecting mixed trends.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$17.6B

Revenue reported for this quarter.

Quarter-over-quarter

+5.4%

Change from the immediately preceding quarter.

Year-over-year

-1.2%

Change from the comparable year-ago quarter.

Trailing four quarters

$62.6B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Mar 30, 2025$13.7B-7.8%
Jun 29, 2025$14.7B+10.3%
Sep 28, 2025$16.7B-5.9%
Dec 31, 2025$17.6B-1.2%

Revenue performance

The quarter's revenue increased from the preceding quarter, yet declined relative to the year-ago period.

Quarterly comparison

Compared with the immediately preceding quarter, revenue grew; compared with the same quarter one year earlier, it decreased.

What to watch

Monitor whether the sequential growth can sustain amid the year-over-year contraction.

Pfizer (PFE) Revenue — Quarter Ended Dec 31, 2025